Tumor organoid model of colorectal cancer (Review)

Chi Yang; Wangwen Xiao; Rui Wang; Yan Hu; Ke Yi; Xuan Sun; Guanghui Wang; Xiaohui Xu

doi:10.3892/ol.2023.13914

Tumor organoid model of colorectal cancer (Review)

Oncol Lett. 2023 Jun 15;26(2):328. doi: 10.3892/ol.2023.13914. eCollection 2023 Aug.

Authors

Chi Yang¹, Wangwen Xiao², Rui Wang³, Yan Hu², Ke Yi², Xuan Sun¹, Guanghui Wang³, Xiaohui Xu^{1

2}

Affiliations

¹ Department of Gastroenterology, The First People's Hospital of Taicang, Taicang Affiliated Hospital of Soochow University, Soochow Medical College of Soochow University, Suzhou, Jiangsu 215400, P.R. China.
² Central Laboratory, The First People's Hospital of Taicang, Taicang Affiliated Hospital of Soochow University, Soochow Medical College of Soochow University, Suzhou, Jiangsu 215400, P.R. China.
³ School of Pharmacy, Soochow Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Abstract

The establishment of self-organizing 'mini-gut' organoid models has brought about a significant breakthrough in biomedical research. Patient-derived tumor organoids have emerged as valuable tools for preclinical studies, offering the retention of genetic and phenotypic characteristics of the original tumor. These organoids have applications in various research areas, including in vitro modelling, drug discovery and personalized medicine. The present review provided an overview of intestinal organoids, focusing on their unique characteristics and current understanding. The progress made in colorectal cancer (CRC) organoid models was then delved into, discussing their role in drug development and personalized medicine. For instance, it has been indicated that patient-derived tumor organoids are able to predict response to irinotecan-based neoadjuvant chemoradiotherapy. Furthermore, the limitations and challenges associated with current CRC organoid models were addressed, along with proposed strategies for enhancing their utility in future basic and translational research.

Keywords: colorectal cancer; drug therapy; organoids; tumor microenvironment; tumor model.

Publication types

Review

Grants and funding

This study was supported by the National Natural Science Foundation of China (grant no. 81703022), Jiangsu Province Key Youth Talents Project (grant no. QNRC2016262), Gusu Health Talents Training Project (grant no. GSWS2019078), the guiding project of Jiangsu Provincial Health Committee (grant no. Z2021077), the project of Suzhou Medical health science and technology innovation (grant no. SKY2022029) and the project of Taicang Science and Technology Bureau (grant no. TC2018JCYL20).